Want to see AIFF full AI Analyst Report?
Top Page
Firefly Neuroscience
(NASDAQ:AIFF)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▲(47.06% Upside)
Action:Reiterated
Date:09/18/26
The score is primarily held back by weak financial performance—deep losses and persistent negative free cash flow despite improving revenue and a debt-free balance sheet. Technicals are modestly supportive in the near term (above 20/50-day averages, RSI ~63) but not confirmed by longer-term trends and MACD. Valuation remains challenged due to negative earnings, while corporate events are mixed with both capital-structure tightening and financing uncertainty.
Positive Factors
Debt-free balance sheet
The absence of reported debt materially reduces financial risk and avoids interest burdens that could further pressure a loss-making business. Combined with the larger equity base, this gives Firefly greater flexibility to fund operations, pursue development, and manage financing decisions over the next several quarters.
Negative Factors
Deep operating losses
Firefly remains far from break-even because its expense base is substantially larger than its current revenue run-rate. Although losses narrowed year over year, the magnitude of the deficit limits internal reinvestment capacity and makes successful revenue scaling essential to establishing sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of reported debt materially reduces financial risk and avoids interest burdens that could further pressure a loss-making business. Combined with the larger equity base, this gives Firefly greater flexibility to fund operations, pursue development, and manage financing decisions over the next several quarters.
Read all positive factors
Firefly Neuroscience (AIFF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.08M
Dividend YieldN/A
Average Volume (3M)71.80K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth320.33%
EPS Growth79.09%
CountryUS
Employees17
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-0.64
Shares Outstanding15,690,316
10 Day Avg. Volume58,306
30 Day Avg. Volume71,801
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.51
Price to Sales (P/S)10.11
P/FCF Ratio-1.39
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue10.73
Enterprise Value/Gross Profit24.06
Enterprise Value/Ebitda-2.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Firefly Neuroscience Business Overview & Revenue Model
Company Description
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected ...
Firefly Neuroscience Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.80M | 1.14M | 108.00K | 498.00K | 0.00 | 32.00K |
| Gross Profit | 802.00K | 645.00K | 41.00K | 498.00K | 0.00 | 32.00K |
| EBITDA | -8.87M | -19.55M | -10.32M | -2.58M | -3.20M | -3.82M |
| Net Income | -9.11M | -19.88M | -10.46M | -2.60M | -3.79M | -4.38M |
Balance Sheet | ||||||
| Total Assets | 16.77M | 10.48M | 4.60M | 2.64M | 135.00K | 953.00K |
| Cash, Cash Equivalents and Short-Term Investments | 9.23M | 2.75M | 1.81M | 2.14M | 58.00K | 653.00K |
| Total Debt | 0.00 | 0.00 | 694.00K | 0.00 | 0.00 | 1.79M |
| Total Liabilities | 2.10M | 2.84M | 4.98M | 2.53M | 2.25M | 3.97M |
| Stockholders Equity | 14.66M | 7.64M | -375.00K | 109.00K | -2.11M | -3.01M |
Cash Flow | ||||||
| Free Cash Flow | -7.20M | -8.32M | -6.57M | -2.56M | -2.89M | -3.82M |
| Operating Cash Flow | -6.99M | -8.19M | -6.16M | -2.17M | -2.89M | -3.82M |
| Investing Cash Flow | -209.00K | -2.49M | -477.00K | -386.00K | 262.00K | 1.60M |
| Financing Cash Flow | 10.51M | 11.62M | 6.30M | 4.64M | 2.04M | 2.04M |
Firefly Neuroscience Technical Analysis
Positive
1.02
Price Trends
1.11
Positive
1.38
Negative
1.38
Negative
Market Momentum
-0.01
Negative
62.97
Neutral
22.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIFF, the sentiment is Positive. The current price of 1.02 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.11, and below the 200-day MA of 1.38, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 62.97 is Neutral, neither overbought nor oversold. The STOCH value of 22.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIFF.
Firefly Neuroscience Risk Analysis
Firefly Neuroscience disclosed 73 risk factors in its most recent earnings report. Firefly Neuroscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Firefly Neuroscience Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $3.68B | -254.26 | -8.97% | ― | 25.58% | 85.38% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
49 Neutral | $20.08M | -1.98 | -90.17% | ― | 320.33% | 79.09% | |
48 Neutral | $100.80M | -5.42 | -50.17% | ― | ― | 70.27% | |
43 Neutral | $12.38M | -1.52 | -126.45% | ― | -1.67% | 7.34% |
* Technology Sector Average
AIFF
Firefly Neuroscience
1.26
-1.63
-56.40%
IRTC
Irhythm Technologies
109.33
-65.69
-37.53%
NMTC
NeuroOne Medical Technologies
1.39
-4.19
-75.09%
CGTX
Cognition Therapeutics
1.04
-0.36
-25.71%
Firefly Neuroscience Corporate Events
Executive/Board Changes
Firefly Neuroscience Reshapes Finance and Accounting Leadership
Neutral
Sep 14, 2026
On September 8, 2026, Firefly Neuroscience’s board of directors terminated Chief Financial Officer Paul Krzywicki, effective September 24, 2026, with the company stating the decision did not stem from disagreements over operations, policies ...
Business Operations and StrategyShareholder Meetings
Firefly Neuroscience Expands Incentive Plan, Tightens Capital Structure
Positive
Aug 7, 2026
On August 5, 2026, Firefly Neuroscience stockholders approved an amendment to the 2024 Long-Term Incentive Plan, adding 2,000,000 shares to the pool available for equity awards and updating the plan’s evergreen share replenishment feature. T...
Business Operations and StrategyPrivate Placements and Financing
Firefly Neuroscience Ends Financing Agreement, Explores New Options
Negative
Jun 26, 2026
Firefly Neuroscience, Inc. had previously entered into a securities purchase agreement with an accredited investor on May 6, 2026, to sell up to 666,667 units at $1.50 per unit, targeting gross proceeds of up to $1 million. On June 25, 2026, the c...
Business Operations and StrategyExecutive/Board Changes
Firefly Neuroscience Reassigns Former CTO to AI Leadership
Positive
Jun 22, 2026
On June 18, 2026, Deel Innovation Ltd., a consulting provider to Firefly Neuroscience, entered into an employment agreement with former Chief Technology Officer Gil Issachar, under which he now serves as Head of AI and Neuroscience at Firefly. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.